SHARE
SCB Asset Management Company Limited (SCBAM) would like to inform the unitholder that SCBIHEALTH has been approved by the Securities and Exchange Commission Office on the Master Fund change. The Fund’s NAV calculation, subscription and redemption period shall be also updated to be aligned with the new Master Fund. Such change will be effective from 7 October 2024 onwards per following details.
| Subject | Existing | New |
| Master Fund |
Baillie Gifford Worldwide Health Innovation Fund Share Class: B USD ISIN: IE00BGGJJ945 Management Company: Baillie Gifford Investment Management (Europe) Limited Fund Domicile: Ireland Investment Policy: The Master Fund aims to produce capital growth over the long term by investing mainly in global equities selected from companies involved in the healthcare industry and which are innovative in their focus on areas such as diagnostics, treatment and prevention. |
BNP Paribas Funds Health Care Innovators
ISIN: LU0823417067 Management Company: BNP PARIBAS ASSET MANAGEMENT Luxembourg Fund Domicile: Luxembourg Investment Policy: The Master Fund aims to increase the value of its assets over the medium term by investing at least 75% of its assets in equities and/or equity equivalent securities issued worldwide by health care companies that enable or benefit from innovative technologies, including, but not limited to, advances in genetic sequencing, drug delivery, miniaturization etc. Benchmark: MSCI World Health Care 10/40 (EUR) NR |
| NAV Calculation and Announcement |
NAV Calculation: T+1 |
NAV Calculation: T+2 |
| Subscription, Redemption and Settlement Period |
Subscription and Redemption: 08.30 – 14.30 |
Subscription and Redemption: 08.30 – 15.30 |
The primary advantage of this change is to enhance portfolio management for the utmost benefit of unitholders. The Master Fund, BNP Paribas Funds Health Care Innovators, primarily invests in companies that benefit from medical innovations, aligning with SCBIHEALTH’s investment policy. It employs a bottom-up approach with a high-conviction investment portfolio comprising 30-60 stocks across all market capitalizations. Based on its historical performance, the Master Fund demonstrates superior resilience during market downturns. This characteristic is a significant advantage for investors, contributing to portfolio stability and enhancing the potential for long-term growth. Additionally, the Master Fund holds a 5-star rating from Morningstar in the EAA Fund Sector Equity Healthcare category, as of July 31, 2024.
You may visit SCBAM’s website for more details of the Master Fund or contact Client Relations 0-2777-7777 during business days between 08.30 – 17.00 for any further inquiries.
Announced on 6 September 2024
SCB Asset Management Company Limited
SCB LOW VOLATILITY EQUITY FUND (Dividend)
SCB LOW VOLATILITY EQUITY FUND
(Accumulation)
SCB Low Volatility Equity RMF
SCB Global Equity Absolute Return Fund (Accumulation)
SCB Mixed – Spicy Fund (Accumulation)
SCB Income Fund (Accumulation)
SCB Income Fund (Auto Redemption)
SCB Global Robotics Fund (Accumulation)
